Crestwood Advisors Group LLC Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)

Crestwood Advisors Group LLC lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 92.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,257 shares of the biopharmaceutical company’s stock after purchasing an additional 5,400 shares during the period. Crestwood Advisors Group LLC’s holdings in Bristol-Myers Squibb were worth $637,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Capital Advisors Ltd. LLC lifted its holdings in Bristol-Myers Squibb by 8.5% during the fourth quarter. Capital Advisors Ltd. LLC now owns 2,659 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 208 shares during the period. Birchcreek Wealth Management LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth $216,000. Y Intercept Hong Kong Ltd purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth $2,877,000. Union Bancaire Privee UBP SA acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $312,000. Finally, Delta Financial Group Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth $2,490,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,823 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares of the company’s stock, valued at $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Up 0.6 %

Shares of NYSE BMY opened at $58.25 on Wednesday. The firm has a market cap of $118.21 billion, a price-to-earnings ratio of -13.18, a PEG ratio of 2.07 and a beta of 0.45. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.10. The business’s 50 day moving average is $57.05 and its two-hundred day moving average is $54.56.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were given a $0.62 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.26%. Bristol-Myers Squibb’s payout ratio is presently -56.11%.

Wall Street Analyst Weigh In

BMY has been the topic of several research reports. BMO Capital Markets upped their target price on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research report on Tuesday, November 12th. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Friday, February 7th. Finally, Bank of America restated a “neutral” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.